Document:

<PAGE>

[CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR THE PORTIONS OF THIS EXHIBIT
MARKED WITH ASTERISKS (***).]

                                                                    EXHIBIT 10.9

                              RESEARCH AGREEMENT
                              ------------------

     This Research Agreement (the "Agreement") is made as of this 18th day of
November, 1999 by and between YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW
UNIVERSITY OF JERUSALEM, 46 Jabotinsky Street, Jerusalem ("Yissum") of the one
part, and LAKARO BIOPHARMACEUTICALS, INC. (the "Company") of the other part.

     WHEREAS, the Company, pursuant to the License Agreement of even date
herewith, between CMCC and the Company (the "License Agreement"), is the
exclusive licensee of certain rights to certain patents and patent applications
(the "Inventions") currently under development by Dr. Shmuel Ben-Sasson
(hereinafter, "Inventor") at Yissum;

     WHEREAS, the Company wishes to finance research which is being carried out
and conducted in the Hebrew University of Jerusalem  (hereinafter referred to as
the "University") under the supervision of the Inventor, subject to and as
detailed in the research program annexed hereto as an integral part hereof
(hereinafter referred to as the "Research"); and

     WHEREAS, the Company has entered into a definitive license agreement (the
"License Agreement") with Children's Medical Center Corporation ("CMCC") of even
date herewith for the purpose of developing and commercializing the technology
being developed at the University by the Researcher.

     WHEREAS, Yissum is the exclusive representative of the University and of
the Researcher in all aspects relating to the Research and/or this Agreement and
all rights whatsoever in the Research and/or the results thereof shall belong to
Yissum and/or CMCC; and

     WHEREAS, the University has the facilities and the personnel with the
requisite skills, experience, and knowledge to undertake such Study (as
hereinafter defined); and

     WHEREAS, Yissum agrees to procure the performance of the Research in
accordance with the terms and conditions of this Agreement below.

     NOW, THEREFORE, the parties agree as follows:

1.   Recitals and Definitions.  The recitals hereto constitute an integral part
     ------------------------
hereof.  In this Agreement the following expressions shall have the meanings
appearing alongside them.

     (a)  "University" shall mean the Hebrew University of Jerusalem and/or each
of its branches.

     (b)  "Research" shall mean the research which is being carried out and
conducted in the University subject to and as detailed in the Research program
annexed hereto as an integral part hereof and marked as Appendix "A".

     (c)  "Research Program" shall mean the subject matter of the Research as
set forth in Appendix "A".

                                       1
<PAGE>

     (d)  "Research Results" shall mean the tangible and intangible information
arising out of the Research, including, without limitation, any patents, patent
applications, information, material, results, devices and any know-how arising
therefrom.

     (e)  "Research Period" shall mean the period set forth in the Research
Program for the performance of the Research.

     (f)  "Know-how" shall mean the Research Results and/or the patents and/or
the patent registration applications detailed in Appendix "B".

     (g)  "Agreement" shall mean this agreement together with all the appendices
and annexes hereto.

     (h)  "Consideration" shall mean the amounts set forth in Appendix C.

2.   The Research and its Performance
     --------------------------------

     (a)  Yissum hereby agrees to procure its performance in the University, all
as provided below in this Agreement.

     (b)  Yissum shall procure the conduct of the Research in accordance with
the Research Program during the Research Period and in accordance with the other
terms and conditions as provided in Appendix "A" hereto. The Company is entitled
to request that Yissum add to or introduce changes in the Research during the
course of the performance of the Research, provided that such additions or
changes as aforesaid are coordinated a reasonable time in advance and also
provided that the Consideration is adjusted to the reasonable satisfaction of
Yissum.

     (c)  Within sixty (60) days from the date hereof and from time to time
thereafter, the Company agrees to meet with the Researchers to establish
research milestones ("Milestones") which shall be set through good faith
negotiations for the dates which are twelve (12), eighteen (18), twenty-four
(24) and thirty (30) months from the date of this Agreement and to review the
progress towards the attainment of the Milestones. Such Milestones shall be
added to Appendix A and made a part of this Agreement.

     (d)  This Agreement may be extended for additional one-hundred-eighty (180)
day periods upon the mutual written agreement of the parties, provided the
parties shall have reached an agreement regarding the amount of financing the
Company shall pay to Yissum for the extended period or periods.

     (e)  On a semiannual basis and commencing six (6) months after the
commencement of the Research and upon the expiration of the Research Period or
of the extended period, Yissum shall give the Company a report detailing the
results and conclusions of the Research (hereinafter referred to as the
"Scientific Report"). For the avoidance of doubt, it is hereby expressed that
the Agreement in general and this clause in particular shall not constitute an
obligation and/or confirmation on the part of Yissum that any results and/or
conclusions will be achieved in consequence of the performance of the Research
and/or that a Product may be developed as a result thereof.

     (f)  The Company may at any time during the Research Period obtain any
information relating to the Research's performance from Yissum, including plans
and

                                       2
<PAGE>

documents relating thereto. The Company's representative may attend the site
where the Research is being carried out, provided that the time of such visit is
coordinated in advance with Yissum and the Researchers.

3.   Improvements and Patent Rights.  It is recognized and understood that
     ------------------------------
certain existing Inventions and technologies are the separate property of the
Company or Yissum and are not affected by this Agreement, and neither Party
shall have any claims to or rights in such separate inventions and/or
technologies. Any improvements or inventions ("Improvements") to the Patent
Rights (as defined in Article I(I) of the License Agreement) resulting from the
Research (including, without limitations, intellectual property rights set forth
in Article I(I)(1)-(5)) shall be promptly disclosed in writing to the Company,
but in no event shall disclosure of such Improvements by Yissum, the Principal
Investigator or other researcher be made to any third party unless in accordance
with this paragraph 3; provided, however, that title to any new Improvements
resulting from the Study shall be in Yissum.  Inventorship of such Improvements
shall be determined in accordance with patent law or by mutual agreement if the
Improvements are not patentable.  To the extent that Yissum owns the rights of
sole or joint inventorship of such Improvements, the Company is hereby granted,
without further consideration, an exclusive right and license to any
Improvements upon the terms and conditions set forth in the License Agreement
and such Improvements shall be included as a part of the Patent Rights thereof.
In addition, if any such Invention is not patentable or otherwise protectable as
a trade secret, the Company shall have the right to use, develop, manufacture,
have manufactured, market and employ any such unpatentable Inventions without
the obligation to pay any royalties so long as the license is in effect or the
information is in the public domain.

4.   Patent Prosecution.  Any patents and/or patent applications arising out of
     ------------------
the Research or contained in the Research Results shall be diligently prosecuted
in accordance with Article VI of the License Agreement.

5.   Finance of the Research
     -----------------------

     (a)  In Consideration for the performance of the Research and in order to
finance it, the Company undertakes to pay, or procure its subsidiary, if any, to
pay to Yissum the amount detailed in the appendix annexed hereto as an integral
part hereof and marked as Appendix C.

     (b)  It is agreed between the parties that the provisions of this Agreement
shall not prevent Yissum, the University and/or the Researchers from obtaining
gifts, grants, donations or other charitable contribution from other entities
for the Research, provided that such entities shall not be granted rights
(commercial, financial or otherwise) in the Research, the Research Results or
the Know-how prejudicing the rights granted to the Company in accordance
herewith.

     (c)  Should the Research Period be extended as detailed in clause 2(c)
above or for any other reason as agreed to between the parties, the parties
shall determine by agreement the supplemental finance for the period of the
extension and such fee shall be added to the Consideration. The terms and
conditions of this Agreement shall apply, mutatis mutandis, to the supplemental
Consideration.

     (d)  Yissum shall submit to the Company every six (6) months commencing
from the date of commencement of the Research Period (hereinafter referred to as
the "Reporting

                                       3
<PAGE>

Period") a report of expenses relating to the Research (hereinafter referred to
as the "Expense Report"). The Expense Report shall detail all the expenses
incurred relating to the Research and shall be submitted to the Company within
forty-five (45) days after the expiration of the Reporting Period. A summary
Expenses Report shall be submitted sixty (60) days after the expiration of the
Research Period, and should the Research Period be extended, 60 days after the
expiration of each extended period.

     (f)  If this Agreement is terminated prior to the end of the Research
Period, all funds paid up to the time of termination shall be considered non-
recoverable by the Company.  Additionally, Yissum's sole damages and remedy
shall be to recover from the Company all amounts owed for work completed and
non-cancelable expenses committed through the date of termination based pro-rata
upon the figures in Appendix C, provided, however, that the Company shall
reimburse Yissum for non-cancelable employment obligations entered into by
Yissum as a result of this Agreement, except for the Principal Investigator, for
the remainder of any Agreement year which has begun and within such year the
termination has occurred.  Paragraphs 3 (Inventions and Patent Rights), 7
(Confidential Information), 8 (Use of Name), 9 (Publication), and 10
(Indemnification) shall survive any termination of this Agreement.

6.   Ownership
     ---------

     Yissum and/or CMCC are the owners of the entire right, title and interest
in the Know-how and the Research Results, as more fully described in Appendix B
attached hereto, and the inventions described and/or claimed therein.

7.   Confidentiality
     ---------------

     (a)  The Company and Yissum warrants and undertakes that during the term of
this Agreement and subsequent thereto, it shall maintain confidentiality and
also be liable for its employees and/or representative and/or persons acting on
its behalf maintaining absolute confidentiality of all information, details and
data which is in and/or comes to its knowledge and/or that of its employees,
representatives and/or any person acting on its behalf directly or indirectly
relating to the Research, the Know-how, the Product. The Company and Yissum
undertake not to convey or disclose anything in connection with the foregoing to
any entity.

     (b)  The obligation contained in this clause shall not apply to information
which is:

          (i)   received by the Company from a third party rightfully in
possession of the same and having the right to disclose the same; or

          (ii)  now or hereafter in the public domain through no fault of the
Company; or

          (iii) disclosed without confidentiality restrictions by the Company
pursuant  to prior specific written approval of Yissum; or

          (iv)  required to be disclosed by legal, administrative or judicial
process; or

                                       4
<PAGE>

          (v)   approved for public release by written authorization by the
Disclosing Party.

     (c)  The Company may disclose details and information as aforesaid to its
employees, sub-licensees, potential sub-licensees and other third-parties, if
such sub-licensees, potential sub-licenses or other third-parties have executed
an undertaking for the maintenance of confidentiality as mentioned below.

     (d)  Without prejudice to the foregoing, the Company shall not mention the
University's name in any manner or for any purpose in connection with this
Agreement, the subject of the Research or any matter relating to the Research or
the Know-how, without obtaining Yissum's prior written consent, unless the
Company reasonably determines that such use of name may be required by law. The
Company shall further procure that any entity connected with and subordinate to
it shall not mention the University's name or the subject of the Research or any
matter relating to the Research as aforesaid unless such information is
otherwise publicly available.

     (e)  Yissum shall execute and procure that its Researchers, employees
and/or any other person connected with it with regard to the License executes an
undertaking for the maintenance of confidentiality in the form annexed hereto as
an integral part hereof and marked as Appendix E.

     (f)  The Company shall execute and procure that its employees and every
person connected with it or engaged by it executes an undertaking for the
maintenance of confidentiality in the form contained in Appendix E.

     (g)  The breach of this clause, including the sub-clauses hereof, by any
person or entity other than Yissum or the Company shall not be deemed a breach
of the Agreement, if Yissum or the Company prove that they took all reasonable
steps to avoid the breach.

     (h)  The termination of this Agreement shall not release the Company from
its obligations pursuant to this clause, including the sub-clauses hereof.

8.   Use of a Party's Name.  Neither Party will, without the prior written
     ---------------------
consent of the other Party, use in advertising, publicity, or otherwise, the
name, trademark, logo, symbol, or other image of the Party or that Party's
employee or agent;  provided, however, that Yissum acknowledges and agrees that
the Company may Yissum's name and references to this Agreement and related
agreements and the names of the their employees (including, without limitation,
the Principal Investigator) as they may relate to such agreements in any private
placement memorandum, prospectus, registration statement or any similar
disclosure document used by the Company for capital raising and financing
purposes as may be required by and in accordance with applicable law without
such prior written consent.  Yissum may list the existence of this Agreement in
its internal documents and annual reports and databases which are available to
the public and identify the Project by title, Principal Investigators, the
Company, and period and amount of funding.

9.   Publications.  In the event that Yissum desires to publish or disclose, by
     ------------
written, oral or other presentation, the Patent Rights or any material
information related thereto which may jeopardize the aforementioned rights then
Yissum shall notify the Company in writing in accordance with Article XIV of
their intention at least fifteen (15) days prior to any speech, lecture or other
oral presentation and at least sixty (60) days prior to any written or

                                       5
<PAGE>

other publication or disclosure. Yissum shall include with such notice a
description of any such proposed oral presentation or, in any proposed written
or other disclosure, a current draft of such proposed disclosure or abstract.
The Company may request that the Inventors and Yissum, no later than thirty (30)
days following the receipt of such notice, delay such publication or disclosure
in order to enable the Company to request that Yissum file, or have filed on its
behalf, a patent application, copyright or other appropriate form of
intellectual property protection related to the information to be disclosed.
Upon receipt of such request, Yissum shall arrange for a delay in such
publication or disclosure until such time as Yissum has filed, or had filed on
its behalf, such patent application, copyright or other appropriate form of
intellectual property protection in form and in substance reasonably
satisfactory to the Company and Yissum. If Yissum receives no such request from
the Company to delay publication or disclosure, then Yissum may submit such
material for publication or presentation or make such other publication or
disclosure. If Yissum has not filed, or had filed on its behalf, such patent
application, copyright or other appropriate intellectual property protection
within thirty (30) days of a request by the Company to Yissum to do so, then the
Company shall have the right but not the obligation to file on behalf of Yissum
any appropriate intellectual property protection upon notice to Yissum within
fifteen (15) days of the expiration of said thirty (30) day period. Upon receipt
of such notice, Yissum shall arrange for a delay in publication or disclosure
until such time as the Company has filed such patent application, copyright or
other appropriate form of intellectual property protection which the Company
agrees to file as soon as is reasonably practicable provided, however that said
deferral shall not exceed ninety (90) days from the receipt of such notice.

10.  Liability and Indemnity
     -----------------------

     (a)  The Company agrees to indemnify, hold harmless and defend Yissum, its
trustees, officers, employees, and agents from and against any and all claims,
suits, losses, damages, costs, fees, expenses (including reasonable attorney's
fees), and other liabilities asserted by third parties, both government and non-
government, resulting from or arising out of the Study carried out pursuant to
this Agreement; provided, however, that the Company shall not be liable for (a)
the negligence, intentional wrongdoing, or failure  of the Researcher to follow
the Research Program, Yissum, its trustees, officers, employees and agents and
(b) any and all claims for damages to Yissum property or for bodily injury,
death or property damage to employees of Yissum or to any third party acting on
behalf of or under the authorization of Yissum arising out of the performance of
this Agreement, except for the negligent or intentional acts solely of the
Company with respect to both (a) and (b) above.  Without limiting the foregoing,
except for the negligence or willful misconduct of Yissum, the Company agrees to
indemnify and defend Yissum from all liabilities, demands, damages, expenses and
losses (including reasonable attorney fees and expenses of litigation) arising
out of the use by the Company, or any party acting on behalf of or under
authorization from the Company, of the Research Results or out of any use, sale
or other disposition by the Company, or by any party acting on behalf of or
under authorization from the Company, of products made or developed
incorporating the Research Results or made by a process incorporating the
Research Results.

     (b)  Yissum agrees to indemnify, hold harmless and defend the Company, its
directors, officers, employees, and agents from and against any and all claims,
suits, losses, damages, costs, fees, expenses (including reasonable attorney's
fees), and other liabilities asserted by third parties, both government and non-
government, resulting from or arising out of the Research carried out pursuant
to this Agreement as a result of the negligence, intentional wrongdoing of
Yissum, its trustees, officers, employees and agents and any and

                                       6
<PAGE>

all claims for bodily injury, death or property damage to employees of Yissum or
to any third party acting on behalf of or under the authorization of Yissum
arising out of the performance of this Agreement, provided, however, that Yissum
shall not be liable for the negligent or intentional acts solely of the Company.
Yissum, its trustees, officers, employees and agents shall incur no liability
under this Section 10(b) with respect to any claims, suits, losses, damages,
costs, fees, expenses (including reasonable attorney's fees), and other
liabilities asserted by third parties, both government and non-government, as a
result of product liability and/or patent infringement.

11.  Term and Termination
     --------------------

     (a)  Subject to the terms and conditions as set forth in this Agreement,
the term of this Agreement shall be for a period of two (2) years.

     (b)  Without prejudice to Yissum's rights at law or pursuant to this
Agreement, Yissum may terminate this Agreement by notice given to the Company if
a receiver or liquidator is appointed for the Company and/or the Company passes
a resolution for voluntary winding up or a winding up application is made
against the Company and not set aside within sixty (60) days;

     (c)  Without prejudice to the Company's rights pursuant to this Agreement
or at law, the Company shall be entitled to terminate the Agreement on the
winding up or bankruptcy of Yissum or if Yissum should commit a breach of the
Agreement and not remedy the breach within thirty (30) days of receiving notice
thereof.

     (d)  Should the Inventor fail to attain any Milestone then the Company
shall be entitled to terminate this Agreement and shall not be obligated to
continue to finance the Research contemplated under this Agreement.

     (e)  Should the Inventor become unable to complete or continue the Research
for any reason, then Yissum and/or CMCC shall propose a substitute researcher
(the "Substitute Researcher") to the Company.  In the event that the Substitute
Researcher is not reasonably acceptable to the Company, then the Company shall
be entitled to terminate this Agreement and shall not be obligated to continue
to finance the Research contemplated under this Agreement.

     (f)  Upon termination of this Agreement other than pursuant to the above
paragraphs (c) and (d), the Company shall return to Yissum, within fourteen (14)
days of such termination, all material relating to the Research, Know-How and/or
Research Results, and it may not make any further use thereof. Notwithstanding
the foregoing, the termination of this Agreement by the expiry of the term set
forth in subparagraph (a) above, provided that all payments due Yissum shall
have been paid according to the terms of this Agreement, shall not be considered
a termination pursuant to this subparagraph and shall not require the return by
the Company of any materials relating to the Research, Know-How and/or Research
Results or the cessation of the use thereof.

     (g)  Upon termination of this Agreement, Yissum shall refrain from selling
any shares of common stock of the Company and exercising any warrants owned or
possessed by Yissum and shall return any such shares or warrants to the Company
within fourteen (14) days of such termination.

                                       7
<PAGE>

     (h)  Termination of this Agreement pursuant to this Article 11 shall not
constitute a breach of, nor result in the termination of, the License Agreement.

                                       8
<PAGE>

12.  Governing Law
     -------------

     The provisions of this Agreement and everything concerning the relationship
between the parties in accordance with this Agreement shall be governed by
Israeli law and jurisdiction shall be granted only to the appropriate court in
Jerusalem.

13.  Arbitration
     -----------

     (a)  Any differences or disputes arising between the parties in connection
with the Agreement and/or its interpretation, performance and/or breach shall be
referred for the decision of a tribunal of arbitrators.  Each of Yissum and the
Company shall select one arbitrator.  The third arbitrator shall be selected by
mutual agreement of the first two.

     (b)  Should the selected arbitrators be unable to reach agreement as to the
third arbitrator's identity, the arbitrator shall be appointed by the President
of the Israel Bar on the application of either of the parties.

     (c)  The arbitration shall be held in Israel. The arbitrator shall be
released from the civil procedure and laws of evidence but shall be bound by the
substantive law of Israel and be liable to give grounds for his decision.

     (d)  The arbitrators' decision shall be final and bind the parties.

     (e)  The parties execution of this Agreement shall constitute the execution
of an arbitration deed.

14.  Miscellaneous
     -------------

     (a)  This Agreement and the rights and duties appertaining thereto may not
be assigned by either party without first obtaining the written consent of the
other.  Any such purported assignment, without the written consent of the other
party, shall be null and of no effect. Notwithstanding the foregoing, Yissum or
the Company may assign this Agreement to the following:

          (ii)  a purchaser, merging or consolidating corporation or acquiror of
substantially all of Yissum's or the Company's assets or business; or

          (iii) an Affiliate of Yissum or the Company subject to the consent of
the other Party which consent shall not be unreasonably withheld.

     (b)  The failure or delay of a party to the Agreement to claim the
performance of an obligation of the other party shall not be deemed a waiver of
the performance of such obligation.

     (c)  Each party shall bear its own legal and other expenses involved in the
making of this Agreement.

     (d)  The headings to the clauses in this Agreement are for the sake of
convenience only and shall not serve in the Agreement's interpretation.

                                       9
<PAGE>

     (e)  This Agreement constitutes a full and complete agreement between the
parties and may only be amended by a document signed by both parties.

     (f)  The appendixes annexed hereto constitute an integral part hereof and
shall be read jointly with its terms and provisions.

15.  Notices
     -------

     All notices and communications pursuant to this Agreement shall be made in
writing and sent by registered mail to or served at the following addresses:

     If to Yissum:       Yissum Research Development Company
                         of the Hebrew University of Jerusalem
                         POB 4279, Jerusalem.

     If to the Company:  Lakaro Biopharmaceuticals, Inc.
                         216 Jaffa Road
                         Jerusalem 94383
                         Att: General Counsel

or such other address furnished in writing by one party to the other. Any notice
sent as aforesaid shall be deemed to have been received four days after being
posted by registered mail or one day after personal service, as the case may be.

AS WITNESS THE HANDS OF THE PARTIES:

                            YISSUM RESEARCH DEVELOPMENT
                            COMPANY OF THE HEBREW

                            By:     /s/ Moti Perlmutter
                                    ----------------------------
                            Name:   Moti Perlmutter
                            Title:  Managing Director

                            LAKARO BIOPHARMACEUTICALS, INC.

                            By:     /s/ Ira Weinstein
                                    ----------------------------
                            Name:   Ira Weinstein
                            Title:  Treasurer

                                       10
<PAGE>

[CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR INFORMATION REDACTED FROM THIS
PAGE.]

                                  APPENDIX A

                Scientific Agenda for KINASE Technology (2000)

                                      ***
                       (paragraph intentionally omitted)

                                       11
<PAGE>

[CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR INFORMATION REDACTED FROM THIS
PAGE.]

                                      ***
                       (paragraph intentionally omitted)

                                       12
<PAGE>

                           APPENDIX B - THE KNOW-HOW

Patent Applications

1.   Short Peptides Which Selectively Modulate the Activity of Serine/Threonine
     Kinases - CMCC 590 - Filed in U.S. (08/861,338), PCT (US98/10319), EPO
     (98922571.8), Japan, China, Canada, Australia.

2.   Design of Short-Peptides That Selectively Modulate Intracellular
     Signaling - CMCC 547 - Filed in U.S.(08/861,153), PCT (US98/10321), EPO
     (98922451.4), Japan, China, Canada, Australia

3.   Short Peptides Which Selectively Modulate the Activity of Protein Kinases -
     CMCC - 679 - Filed in U.S. (09/161,094), PCT (US99/22106).

4.   Short Peptides from the B4 and B5 Regions of Protein Kinases Which
     Selectively Modulate Protein Kinase Activity - CMCC 775 - Filed in the U.S.
     (09/458,491)

                                   Know-How

                                       13
<PAGE>

                          APPENDIX C - CONSIDERATION

        The Company will pay to Yissum the total amount of US$466,000 per year
for a two (2) consecutive years as payable in equal quarterly installments
commencing December 15, 1999, and to be made every three (3) months thereafter,
provided that the Research has not otherwise been terminated.

                                       14<PAGE>

[CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR THE PORTIONS OF THIS EXHIBIT
MARKED WITH ASTERISKS (***).]

                                                                   EXHIBIT 10.10

                             MANUFACTURING AGREEMENT

                                     Between

OPOCRIN S.P.A. - having its registered office at via Pacinotti, 3 - 41040 Corlo
di Formigine (Modena) Italy - Via Pacinotti 3 thereinafter referred to as
OPOCRIN)

                                      and

PARTEC having its registered office at 216 Jaffa Road, Jerusalem 94383 Israel
(thereinafter referred to as PARTEC)

(together called PARTIES)

have agreed, on 16 April 1999, as follows:

                                    WHEREAS

OPOCRIN is an Italian firm which has been producing for many years biological
products in bulk from animal glands and tissues. One of these products is
porcine Sulodexide (Glucuronylglucosaminglycansulphate) . ("DS") which OPOCRIN
has been supplying ALFA WASSERMANN (thereinafter referred to as ALFA) for its
specialty VESSEL, since the date of its commercialization.

PARTEC is an Israeli company specialized in the development and marketing of
biopharmaceutical products and is interested in buying DS from OPOCRIN pursuant
to the terms set forth in this Agreement for a product to be registered,
approved and marketed throughout the world (hereinafter referred to as the
TERRITORY).

                  NOW, THEREFORE, THE PARTIES AGREE AS FOLLOWS:

PRODUCTION

         1.  OPOCRIN agrees to manufacture and PARTEC agrees to purchase amounts
             of DS as PARTEC shall order from time to time for sale by PARTEC,
             or its licensees, affiliates or partners, in the TERRITORY. OPOCRIN
             may, subject to PARTEC's prior written agreement, procure the
             supply of DS to PARTEC from a third party, provided that such
             supply of DS shall conform in all respects to the requirements set
             forth in this Agreement. Partec shall purchase, at a minimum,
             amounts of DS from Opocrin sufficient to meet its needs for all
             clinical trials of Sulodexide during the term of this Agreement.
             Such amounts shall not be less than ten (10) kilograms for the
             Phase II trials and one hundred (100) kilograms for the Phase III
             trials, provided that the conduct of such trials is approved by the
             United States Food and Drug Administration (the "FDA"). Provided
             that OPOCRIN continues to comply with its obligations under this
             Agreement, PARTEC agrees that it shall continue to purchase from
             OPOCRIN all the DS it shall require for the sale and distribution
             of Sulodexide subsequent to the approval of such sale by the FDA,
             and shall recommend to its sublicensees, if any, that they should
             purchase their DS needs from OPOCRIN as well.

         2.  OPOCRIN states that its production of DS is made according to its
             own Drug Master File ("D.M.F.") (which was supplied by ALFA to
             PARTEC under a separate agreement) which shall comply with
             acceptable manufacturing procedures. OPOCRIN agrees to comply in
             the future with the regulations and guidelines promulgated from
             time to time by the FDA and other regulatory authorities and
             current Good Manufacturing Practices ("cGMP"). The above mentioned
             D.M.F. contains an International Validation to exclude the presence
             of conventional viruses in the final product.
<PAGE>

[CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR INFORMATION REDACTED FROM THIS
PAGE.]

         3.  PARTEC's purchase of DS from OPOCRIN shall not confer on PARTEC or
             its licensees, affiliates and/or partners, any licensee, express or
             implied, of OPOCRIN's proprietary, confidential information and
             know-how.

         4.  OPOCRIN requires a minimum lead time from the placement of an order
             up to the date of delivery of forty five (45) Italian business
             days. Provided that PARTEC has not been declared in breach of this
             Agreement by OPOCRIN, OPOCRIN may not refuse a production order
             from PARTEC made pursuant to this Agreement.

         5.  OPOCRIN shall give written notice of at least sixty (60) days to
             PARTEC in the event that it takes any operational or strategic
             decision that could affect, in any way, the timely and appropriate
             fulfillment of OPOCRIN's obligations set forth in this Agreement
             and shall take all necessary steps to prevent such decision having
             such effect.

         6.  OPOCRIN agrees that in the event that (a) it becomes unable to meet
             the needs of PARTEC for the production of DS; or (b) PARTEC has
             sublicensed some or all of its rights to produce and sell
             Sulodexide to a third party that, in spite of PARTEC's
             recommendation to purchase its DS needs from OPOCRIN, chooses to
             move the manufacture of DS from OPOCRIN to another manufacturer,
             OPOCRIN shall transfer, without cost to PARTEC beyond the amounts
             set forth in paragraph 10, below, all information produced by it in
             connection with the fulfillment of its obligations under this
             Agreement, but not proprietary to OPOCRIN, to PARTEC for
             transmission to such other manufacturer. In the event that
             information proprietary to OPOCRIN is required by the other
             manufacturer to produce DS according to the specifications
             required, OPOCRIN shall be entitled to a reasonable license fee for
             such information upon reasonable terms and conditions to be
             negotiated between OPOCRIN and the relevant parties. Absent the
             successful conclusion of such a license agreement to OPOCRIN's
             proprietary information, OPOCRIN shall have no obligation to
             release such proprietary information to PARTEC or any third party.

         7.  OPOCRIN shall supply all the data in its possession required by
             PARTEC in connection with its Initial New Drug application with the
             FDA within twenty one (21) days of PARTEC's request for such data.
             In addition, OPOCRIN, at the appropriate time, shall generate, in
             return for the *** payment set forth in paragraph 10, below, all
             reasonable data necessary to support an approvable D.M.F. and shall
             provide PARTEC with a letter of authorization referencing the
             "closed section" of the D.M.F. for the purposes of complying with
             FDA requirements ("Letter of Authorization").

         8.  As soon as practicable after receiving FDA approval for an
             appropriate IND, and in each September thereafter, the PARTIES
             shall meet to discuss forecasts of PARTEC's anticipated future
             needs. Should the parties agree that PARTEC's anticipated future
             needs exceed OPOCRIN's manufacturing capacity, OPOCRIN shall submit
             a plan within three (3) months of the data such under-capacity
             becomes known to the parties whereby it shall increase such
             capacity.

PRICE, SHIPPING AND TERMS OF DELIVERY

         9.  The per kilogram price for the DS being purchased in connection
             with the Phase II and III clinical trials shall be calculated by
             multiplying the per kilogram United States bulk price of sodium
             heparin at the time each order is placed by PARTEC by a factor of
             ***. The price quoted by OPOCRIN on each order shall be the total
             price invoiced to and paid by PARTEC and shall subsume any and all
             costs incurred by OPOCRIN in the performance and production of such
             order. The parties shall negotiate in good faith the yearly price
             for DS once, and if, the FDA grants its approval for the commercial
             marketing of DS.

         10. Within ten (10) days of the date of the execution of this
             Agreement, PARTEC shall pay to OPOCRIN the amount of ***. This
             payment represents (a) a *** non-refundable payment in
             consideration of the set-up work that OPOCRIN is required to do at
             the proper time to comply with its obligations under this
<PAGE>

[CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR INFORMATION REDACTED FROM THIS
PAGE.]
             Agreement, including, but not limited to, the preparation of the
             D.M.F., the Letter of Authorization and all supporting materials;
             and (b) a *** non-refundable advance against payment for the DS to
             be purchased in connection with the Phase II clinical trials.
             Within ten (10) days of the successful completion of the Phase II
             trials, PARTEC shall pay to OPOCRIN the amount of *** as an advance
             against payment for the DS to be purchased in connection with the
             Phase III clinical trials. In the event that such Phase III trials
             are not held, OPOCRIN shall refund PARTEC this *** prepayment.

         11. OPOCRIN sells DS, C.L.F. arrival at a location of PARTEC's
             choosing. All orders of DS shall be shipped by OPOCRIN in a manner
             that accords with cGMP quality and accreditation requirements.
             OPOCRIN shall provide all reasonable documentation necessary to
             allow the release of the order from any reasonable customs
             restrictions to either PARTEC or a third party designated by
             PARTEC, but shall not be responsible for the final clearing of the
             order from customs. PARTEC shall be responsible for paying all
             appropriate customs duties and charges.

         12. PARTEC shall pay for each order of DS as follows: Fifty percent
             (50%) of the purchase price by Swift telex transfer to OPOCRIN not
             later than 30 (thirty) days from the date of invoice; and fifty
             percent (50%) of the purchase price by Swift telex transfer to
             OPOCRIN not later than fifty (50) days from the date of the AWB
             accompanying the order.

WARRANTY AND QUALITY CONTROL

         13. OPOCRIN warrants:

             a) That DS shall be of the kind and quality described in the
                product specifications of the relative D.M.F.,

             b) That the certificate of analysis which will accompany DS is
                correct and has been produced using accepted procedures and
                standards and by reputable workers, and

             c) That it shall update the D.M.F. as required by relevant
                governmental requirements of the FDA, with a copy to PARTEC.

         14. OPOCRIN agrees that it shall perform a thorough quality control
             check on each batch of DS manufactured pursuant to an order
             submitted by PARTEC and that such check shall include, but not
             necessarily be limited to, characterization and statistical
             analysis of potency.

         15. At least six (6) weeks Prior to the scheduled dispatch of each
             batch of DS, OPOCRIN shall send a sample of the batch to PARTEC, or
             to a third party designated in writing by PARTEC. PARTEC shall have
             the sample analyzed according to the technique set out in the
             D.M.F. and shall communicate the results of the analysis to OPOCRIN
             within four (4) weeks of receipt of the sample. If, after
             conducting the quality testing set forth in this paragraph, a
             sample is determined to have failed such quality testing, OPOCRIN
             shall replace, within twenty (20) Italian business days of receipt
             of written notification by PARTEC, the defective sample at its own
             expense and pay all freight with respect to such replacement.
             PARTEC assumes sole responsibility for determining whether the DS
             is suitable for the use contemplated by PARTEC.

         16. PARTEC, or a third party chosen by it, shall analyze each batch of
             DS upon receipt and shall inform OPOCRIN within fourteen (14) days
             of PARTEC's receipt of the batch of any discrepancy between the
             analysis of the sample provided and approved under paragraph 14,
             above, and the analysis of the batch of DS. If, after conducting
             the analysis set forth in this paragraph, a batch is determined to
             be different than the sample approved under paragraph 14, above,
             OPOCRIN shall replace, within 3 (three) weeks of receipt of written
             notification by PARTEC, the defective batch at its own expense with
             a sample of a new batch in the manner set forth in paragraph 15,
             above, and pay all freight and duty with respect to such
             replacement,
<PAGE>

CONFIDENTIAL

             provided, however, PARTEC has stored the batch under proper
             conditions from the date it received such batch. In the event of
             any disagreement over the analysis conducted pursuant to this
             paragraph, the PARTIES shall use all reasonable means to reach
             agreement.

         17. In the event that the sample or the batch of DS manufactured by
             OPOCRIN to replace the defective batch should itself fail to pass
             the agreed upon quality control standards set forth in the D.M.F.
             and this Agreement, OPOCRIN shall pay any definitively
             ascertainable consequential damages incurred by PARTEC as a result
             of the delay in production of Sulodexide tablets engendered by a
             delay caused by such failure, including, but not limited to, any
             costs associated with the cancellation of tablet manufacturing
             previously scheduled in reliance upon OPOCRIN's timely production
             and delivery of conforming DS, provided that in no event shall such
             damages, even if proven, exceed one-third (1/3) of the purchase
             price of such batch.

         18. Any dispute regarding the quality of a batch delivered pursuant to
             this Agreement that cannot be settled amicably within thirty (30)
             days after it arose shall be referred to an independent testing
             organization that meets appropriate Good Laboratory Practices or to
             a consultant of recognized repute within the European
             Pharmaceutical Industry mutually agreed upon by the parties. If the
             parties cannot agree on the appointment of such organization or
             consultant within forty five (45) days after the dispute arose,
             either party may request the chairman of the International Chamber
             of Commerce to appoint an organization or consultant. The
             determination of the organization or consultant so chosen or
             appointed shall be final and binding on the parties. Any fees and
             expenses of the organization or consultant shall be borne by the
             party against which the determination is made.

RECORDS AND CONFIDENTIALITY

         19. OPOCRIN shall maintain the appropriate records in connection with
             the production of DS for PARTEC pursuant to this Agreement. At
             least once in each six (6) month period (beginning with the
             execution of this Agreement), OPOCRIN shall provide PARTEC with a
             complete set of such records in electronic and typed form. All
             records required to be maintained by this Agreement shall be
             maintained in the English language.

         20. The parties recognize that in the course of fulfilling their
             respective obligations pursuant to this Agreement, they will have
             occasion to disclose to each other confidential and proprietary
             information. Accordingly, they agree to execute a non-disclosure
             agreement substantially in the form as annexed to this Agreement as
             Attachment A.

LIABILITY AND INDEMNIFICATION

         21. Other than as set forth in paragraph 17 above, OPOCRIN shall only
             be liable for any injury, monetary or otherwise, suffered by PARTEC
             or any third party in connection with the Product or its use, if
             and only to the extent such injury was caused by the Product at
             issue not being manufactured in conformance with the requirements
             of the D.M.F. and the other provisions of this Agreement.

         22. PARTEC agrees to indemnify, hold harmless and defend OPOCRIN, its
             trustees, officers, employees, and agents from and against any and
             all claims, suits, losses, damages, costs; fees, expenses
             (including reasonable attorney's fees), and other liabilities
             asserted by third parties, both government and non-government,
             resulting from or arising out of the manufacture and supply of the
             Product carried out pursuant to this Agreement; provided, however,
             that PARTEC shall not be liable for (a) negligence, international
             wrongdoing, or failure to follow the provisions of this Agreement,
             by OPOCRIN, its trustees, officers, employees and agents and (b)
             any and all claims for damages to OPOCRIN property or for bodily
             injury, death or property damage to employees of OPOCRIN arising
             out of the performance of this Agreement, except for the negligent
             or international acts solely of the PARTEC with respect to both (a)
             and (b) above, Without limiting the foregoing, except for the
             negligence or willful misconduct of OPOCRIN, PARTEC agrees to
             indemnify and defend OPOCRIN from all
<PAGE>

CONFIDENTIAL

             liabilities, demands, damages, expenses and losses (including
             reasonable attorney fees and expenses of litigation) arising out of
             the use by PARTEC, or any party acting on behalf of or under
             authorization from PARTEC, of the Product; provided, however, that
             the Product has been manufactured in accordance with the provisions
             of this Agreement. This paragraph shall survive termination of this
             Agreement.

         23. OPOCRIN agrees to indemnify, hold harmless and defend the PARTEC,
             its directors, officers, employees, and agents from and against any
             and all claims, suits, losses, damage, costs, fees, expenses
             (including reasonable attorney's fees), and other liabilities
             asserted by third parties, both government and non-government,
             resulting from or arising out of the manufacture and supply of the
             Product carried out pursuant to this Agreement as a result of the
             negligence, intentional wrongdoing or failure to follow the
             provisions of this Agreement, of OPOCRIN, its trustees, officers,
             employees and agents and any and all claims for bodily injury,
             death or property damage to employees of OPOCRIN or to any third
             party acting on behalf of or under the authorization of OPOCRIN
             arising out of the performance of this Agreement; provided,
             however, that OPOCRIN shall not be liable for the negligent or
             intentional acts solely of PARTEC. Except as provided in paragraph
             (a) above, OPOCRIN, its trustees, officers, employees and agents
             shall incur no liability under this section with respect to any
             claims, suits, losses, damages, costs, fees, expenses (including
             reasonable attorney's fees), and other liabilities asserted by
             third parties, both government and non-government, as a result of
             product liability and/or patent infringements.

TERM AND TERMINATION

         24. Unless otherwise terminated pursuant to this section, this
             Agreement shall remain in force for a period for ten (10) years
             from the date of its execution.

         25. Notwithstanding the provisions of paragraph 24, above, this
             Agreement may be terminated; (a) by either party upon one hundred
             and eighty (180) days advance written notice, provided that should
             such termination notice be given while OPOCRIN is filling a
             previously placed order, such termination shall not take effect
             until such order has been completed and supplied to and paid for by
             PARTEC; or (b) immediately by either party; (i) if one of the
             parties shall be declared insolvent or bankrupt; (ii) if a petition
             is filed in any court and not resolved within sixty (60) days to
             declare one of the parties bankrupt or for a reorganization
             pursuant to the applicable bankruptcy or insolvency laws; or (iii)
             if either party becomes involved in any voluntary bankruptcy or
             other voluntary insolvency proceedings.

         26. Upon the effective date of termination of this Agreement for any
             reason, OPOCRIN shall cease accepting orders from PARTEC for the
             production of DS and the parties shall return any and all
             confidential information belonging to the other party in their
             possession.

MISCELLANEOUS PROVISIONS

         27. Independent Contractors: The relationship between OPOCRIN and
             PARTEC is that of independent contractors and neither's agents,
             representatives, or employees shall be considered employees of the
             other. The parties shall each conduct their respective businesses
             on their own initiative and responsibility and shall have no
             authority to incur any obligations on behalf of the other. Except
             as otherwise set forth in this Agreement, each party shall pay all
             costs and expenses of whatever nature incurred by it in connection
             with its activities under this Agreement, including but not
             limited, to any commissions paid to agents, representatives, or
             employees engaged or employed by it and expenses for travel,
             entertainment, offices or any other items.

         28. Notices: All notices under this Agreement shall be in writing and
             shall be addressed as follows:
<PAGE>

CONFIDENTIAL

        TO OPOCRIN

        Via Pacinotti, 3
        41040 Corlo di Formigne
        Modena, Italy
        Attention: Dr. G. Veronesi

        TO PARTEC
        216 Jaffa Road
        Jerusalem 94383 Israel
        Attention: Bob Trachtenberg
                   General Counsel

             or at such other address as such party may specify in writing from
             time to time. All notices shall be sent by certified or registered
             mail, first-class postage prepaid, by courier delivery or by
             personal delivery, and shall be deemed effective upon actual
             receipt, if by personal or courier delivery, and seven (7) days
             after its dispatch, if by certified or registered mail.

         29. Force Majeure: Neither party shall be liable to the other for its
             failure to perform any of its obligations hereunder during any
             period in which such performance is delayed by circumstances beyond
             its reasonable control, including, but not limited to fire, flood,
             war, embargo, strike, riot, inability to secure materials and
             transportation facilities or the intervention of any governmental
             authority. If such delaying cause shall continue for more than
             ninety (90) days, the party injured by the inability of the other
             to perform shall have the right upon written notice to either (a)
             terminate this Agreement or (b) treat this Agreement as suspended
             during the delay and reduce any commitment in proportion to this
             duration of this delay.

         30. Successors: The terms and conditions of this Agreement shall be
             binding on any successors of either party, where such successor has
             acquired majority control of such party, provided that either party
             or its successor shall be entitled to terminate this Agreement
             pursuant to the provisions of paragraph 25(a), above.

         31. Assignment: Either party shall be entitled to assign its rights
             under this Agreement to a third party upon written notice to the
             other party provided that such third party, (a) in the reasonable
             opinion of the non-assigning party, is capable of fulfilling the
             responsibilities of the assigning party; and (b) adopts the terms
             and conditions of this Agreement in writing delivered to the
             non-assigning party.

         32. Resolution of Disputes: Any disputes arising out of this Agreement
             shall be adjudicated before a single arbitrator pursuant to the
             rules of the International Chamber of Commerce in Geneva,
             Switzerland. Nothing in this paragraph shall prevent either party
             from applying to the appropriate judicial authority in whatever
             jurisdiction the other party may be sued for provisional relief as
             necessary to protect its rights under this Agreement, including,
             but not limited to, applications for injunctions and temporary
             restraining orders, provided that any proceedings beyond the
             proceeding for provisional relief shall be transferred, by consent
             of the parties, to the International Chamber of Commerce for
             adjudication as set forth above. All pleadings, correspondence,
             documents, testimony or other material introduced in any proceeding
             before the International Chamber of Commerce in respect to this
             Agreement shall be in the English language as shall all
             deliberations and proceedings had therein.

         33. Entire Agreement: This Agreement, including the Attachments,
             constitutes the entire agreement between the parties with respect
             to this subject matter and supersedes all previous proposals, both
             oral and written, negotiations, representations, commitments,
             writings and all other communications between the parties. Each
             party acknowledges that in entering into this Agreement, it has not
             relied on any promises, inducements or representations of the other
<PAGE>

             party that are not explicitly set forth in this written Agreement.
             This Agreement may not be released, discharged or modified except
             by an instrument in writing signed by the parties.

         34. Severability: If any provision of this Agreement is determined by a
             court of competent jurisdiction to be invalid or unenforceable,
             such determination shall not affect the validity or enforceability
             of any other part or provision of this Agreement.

         35. Authoritative Language: This Agreement has been drafted and agreed
             to in the English language, and is the authoritative version for
             interpretation and construction by any adjudicative body.

         36. Waiver: No waiver of any breach of any provisions of this Agreement
             shall constitute a waiver unless made in writing and signed by an
             authorized representative of the non-breaching party.

         37. Headings: The headings provided in this Agreement are for
             convenience and organization only and shall not be construed as
             having any substantive effect.

IN WITNESS WHEREOF, each party to this Agreement has executed this Agreement by
a duly authorized representative as of the date set forth above.

OPOCRIN S.P.A.                              PARTEC LTD.

By: /s/ DR. GIORGIO GIUSTI                 By: /s/ MORRIS LASTER
    ------------------------------             -------------------------------
    Dr. Giorgio Giusti
Title:  President                          Title:  CEO
<PAGE>

CONFIDENTIAL

                                 ATTACHMENT A

                                  PARTEC LTD
                       Bio-Medical Venture & Management

                           CONFIDENTIALITY AGREEMENT

This Agreement dated 16 April 1999 shall serve to set forth the terms and
conditions under which Partec Ltd. ("Partec") shall disclose to Opocrin, S.P.A.
("Opocrin") (or the "Receiving Party" or the "Disclosing Party", as appropriate)
proprietary and confidential information to each other, including, but not
limited to any and all information, know-how and data, technical or
non-technical, and product samples and specifications relating to the
manufacture of Sulodexide (the "Information").

1.  The Receiving Party agrees not to divulge the Information which the
Disclosing Party discloses to it and which is marked as "Confidential" (the
"Confidential Information") to any third party or parties, or use said
Confidential Information for any purposes other than those purposes set forth in
the Manufacturing Agreement executed between the parties on 16 April 1999. The
Receiving Party further agrees to limit disclosure only to those of its
officers, employees, agents, affiliates and consultants as the Receiving Party
considers necessary. The Receiving Party shall take all reasonable steps to
prevent the disclosure of the Confidential Information as provided herein. This
obligation shall be binding upon the Receiving Party and shall continue for a
period of five (5) years from each date such Confidential Information is
disclosed to the Receiving Party.

2.  Nothing in the foregoing shall be construed to prevent the Receiving Party
from disclosing or using any Information or from using Confidential Information
which:

(a) was in the Receiving Party's possession or control prior to the date of
disclosure;

(b) was in the public domain or enters into the public domain through no
improper act on the Receiving Party's part or on the part of any of the
Receiving Party's employees;

(c) is approved for public release by written authorization by the Disclosing
Party;

(d) is developed independent of the information derived from the Confidential
Information;

(e) is required to be disclosed by legal, administrative or judicial order; or

(f) is rightfully given to the Receiving Party from sources independent of the
Disclosing Party, its employees or agents.

3.  Oral information which the Disclosing Party wishes to be kept confidential
must be reduced to writing and provided to the Receiving Party within thirty
(30) days of the initial disclosure to the Receiving Party by the Disclosing
Party and conspicuously marked "Confidential."

4.  It is understood and agreed that any and all propriety rights, including,
but not limited to, patent rights, trademarks and proprietary rights in and to
the Confidential Information disclosed to the Receiving Party shall be and
remain in the possession of the Disclosing party and the Receiving party shall
have no right, title or interest in or to any of the Confidential Information.
In addition, nothing in this Agreement shall be construed as establishing any
joint venture or other business relationship, as granting to the Receiving Party
any license or right under any patent rights or as representing any commitment
by either party to enter into any license or other agreement by implication or
otherwise.
<PAGE>

5.  This Agreement constitutes the entire agreement of the parties pertaining to
the subject matter hereof, and all prior or contemporaneous understandings or
agreements, whether written or oral, between the parties with respect to such
subject matter are hereby superseded in their entirety. The parties have made no
agreements, representations or warranties relating to the subject matter of this
Agreement which are not set forth herein and no agreement, understanding or
promise subsequent to the date hereof relating to the subject matter of this
Agreement, the Confidential Information or otherwise between or by one of the
parties hereto shall be binding upon either party unless in writing and executed
by both The Disclosing Party and the Receiving Party and neither party shall be
reasonable in relying on oral statements made by the other which are not
contained in a written agreement.

6.  This Agreement may not be modified, amended or waived in any manner except
by an instrument in writing signed by each of the parties hereto. The waiver by
either party of compliance with any provision of this Agreement by the other
party shall not operate or be construed as a waiver of such party of a provision
of this Agreement. Neither party may assign its rights or obligations hereunder.

7.  This Agreement shall be governed by and construed in accordance with the
laws of the United Kingdom without regard to the conflicts of the law principles
thereof.

8.  In addition, each party warrants to the other party that the person signing
this Agreement on behalf of the such party is fully authorized to bind the such
party to the obligations set forth in this Agreement.

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed
by their respective duly authorized representatives as of the day and year
written above.

OPOCRIN S.P.A.                                PARTEC, LTD.

By: /s/ DR. GIORGIO GIUSTI                    By: /s/ MORRIS LASTER, MD
    ---------------------------------             ------------------------------
Name:  Dr. Giorgio Giusti                     Name:  Morris Laster, MD
Title: President                              Title: CEO

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00012-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00012-of-00352.parquet"}]]